VolitionRx Limited (NYSE: VNRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech [Yahoo! Finance]
Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech
Antech's breakthrough cancer screening tool launches in Europe, supporting early canine cancer detection [Yahoo! Finance]
VolitionRx Limited (NYSE: VNRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.